NCT07354074 2026-03-23Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNovartisPhase 2 Not yet recruiting50 enrolled
NCT04710576 2026-03-16AGAVE-201Syndax PharmaceuticalsPhase 2 Active not recruiting241 enrolled 11 charts 3 FDA
NCT04294641 2026-01-23Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host DiseaseNational Institutes of Health Clinical Center (CC)Phase 2 Completed10 enrolled 15 charts